Futures
Access hundreds of perpetual contracts
CFD
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
CFD
Stock CFD Derivatives
US Stocks
Access real US stocks and ETFs
HK Stocks
Trade quality Hong Kong-listed stocks
Korean Stocks
SK Hynix
Real Korean stocks and top assets
Stock Futures
High leverage, 24/7 trading
Tokenized Stocks
Backed by real stock assets
IPO Access
Unlock full access to global stock IPOs
GUSD
3.8%
Mint GUSD for Treasury RWA yields
Stocks Activities
Trade Popular Stocks and Unlock Generous Airdrops
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
IPO Access
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
Promotions
AI
Gate AI
Your all-in-one conversational AI partner
Gate AI Bot
Use Gate AI directly in your social App
GateClaw
Gate Blue Lobster, ready to go
Gate for AI Agent
AI infrastructure, Gate MCP, Skills, and CLI
Gate Skills Hub
10K+ Skills
From office tasks to trading, the all-in-one skill hub makes AI even more useful.
Ionis Pharmaceuticals' Revenues Rose 85% in 2019
**Ionis Pharmaceuticals **(IONS 17.93%) reported its fourth-quarter and full-year results on Wednesday, and surpassed its revenue and earnings estimates for the year. The company announced over $1.1 billion in revenues for 2019, up from $600 million in 2018. Ionis had $494 million in revenues in the fourth quarter alone.
For 2019, the company reported more than $400 million in net income. And it added another $400 million to its balance sheet, upping the company's cash cushion to $2.5 billion.
Image source: Getty Images
Turning R&D into cash
Ionis has three drugs on the market. The one bringing in the most revenue is Spinraza, a treatment for spinal muscular atrophy. It's marketed by **Biogen **(BIIB 1.32%), which pays royalties to Ionis. In 2019, those payments amounted to $293 million dollars. All in all, Ionis reported $352 million in royalties and other sales revenues for the year.
Most of Ionis' revenues came from its R&D program: It made $771 million from its pipeline in 2019. Pharmaceutical companies are paying a lot of cash to get access to the 28 drugs it has in clinical trials. For 2019, that broke down to $146 million in upfront payments (amortized); $115 million in milestone payments (made when drugs advance in clinical trials); and $490 million in license fees. Income from that last source was up dramatically from 2018's $102 million figure.
Ionis has multiple deals in place with big pharma players, including collaborations with Roche, Pfizer, Novartis, Bayer, AstraZeneca, and GlaxoSmithKline.
Ionis Pharmaceuticals stock was up by more than 1% in mid-afternoon trading Wednesday.